The global orthobiologics market is expected to grow from $4.66 billion in 2017 to reach $8.06 billion by 2023, increasing at a 5.7 percent compound annual growth rate, according to a Market.Biz report.
Biologics
U.K.-based Tissue Regenix Group inked a deal with Premier for TRX's flagship product DermaPure to maintain access to 3,900 hospitals and more than 150,000 healthcare providers in the U.S., according to proactiveinvestors UK.
Biologica Technologies will exhibit clinical data for its ProteiOS growth factor at the American Association of Neurological Surgeons Annual Scientific Meeting in New Orleans.
Medtronic received FDA clearance for a new indication with its Infuse Bone Graft.
The phase I/II U.S. clinical trial testing DiscGenics' IDCT for treating degenerative disc disease is underway.
Advertisement
Datum Orthobiologics was recently founded to provide orthopedic ossification, bone formation and tissue regeneration solutions.
A Siberian tiger at the Szeged Zoo in Hungary received Lipogems stem cell therapy for a hip joint problem April 18, euronews.com reports.
Plano-based Texas Back Institute researchers are assessing the effectiveness of stem cells for revitalizing spinal tissue in a clinical trial.
A new class of clay nanoparticles can lead human mesenchymal stem cells to develop into bone or cartilage cells, Futurity reports.
SpinalCyte is a Houston-based tissue engineering company developing a spinal nucleus replacement solution using human dermal fibroblasts.